Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): An open-label, non-inferiority, randomised controlled trial

  • Kathy Pritchard-Jones
  • , Christophe Bergeron
  • , Beatriz De Camargo
  • , Marry M. Van Den Heuvel-Eibrink
  • , Tomas Acha
  • , Jan Godzinski
  • , Foppe Oldenburger
  • , Liliane Boccon-Gibod
  • , Ivo Leuschner
  • , Gordan Vujanic
  • , Bengt Sandstedt
  • , Jan De Kraker
  • , Harm Van Tinteren
  • , Norbert Graf

Research output: Contribution to journal › Article › peer-review

171 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): An open-label, non-inferiority, randomised controlled trial'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science